Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
Launched by ABBVIE · Jul 23, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of either open-angle glaucoma or ocular hypertension in each eye that require IOP lowering treatment.
- • In the investigator's opinion, patient's IOP is not adequately managed with topical medication for reasons other than medication efficacy (eg, due to intolerance or nonadherence).
- • In the investigator's opinion, both eyes can be treated adequately with topical prostamide, prostaglandin, or prostaglandin analog eye drops as the sole therapy if medication was taken as directed, or with SLT monotherapy.
- Exclusion Criteria:
- • History of previous laser trabeculoplasty
- • History or evidence of complicated cataract surgery: eg, surgery resulting in complicated lens placement (such as anterior chamber intraocular lens implant \[IOL\], sulcus IOL, aphakia, etc) or intraoperative complications (such as a posterior capsular tear \[with or without vitreous loss\], substantial iris trauma, etc) or history of phakic IOL insertion for refractive error correction
- • Intraocular surgery (including cataract surgery) and/or any ocular laser surgery within the 6 months prior to treatment
- • Previous use of commercially available Bimatoprost SR; concurrent enrollment in another Allergan Bimatoprost SR study; or previous enrollment in which an implant was received.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dothan, Alabama, United States
Glendale, Arizona, United States
Prescott, Arizona, United States
Sun City, Arizona, United States
Arcadia, California, United States
Garden Grove, California, United States
Glendale, California, United States
Glendale, California, United States
Irvine, California, United States
Pasadena, California, United States
San Francisco, California, United States
Torrance, California, United States
Delray Beach, Florida, United States
Fort Myers, Florida, United States
Jacksonville, Florida, United States
Jacksonville, Florida, United States
Ocala, Florida, United States
Tamarac, Florida, United States
Tampa, Florida, United States
Morrow, Georgia, United States
Chicago, Illinois, United States
Leawood, Kansas, United States
Edgewood, Kentucky, United States
Louisville, Kentucky, United States
Reading, Massachusetts, United States
Fraser, Michigan, United States
Chesterfield, Missouri, United States
South Orange, New Jersey, United States
Albuquerque, New Mexico, United States
Elizabeth City, North Carolina, United States
High Point, North Carolina, United States
Fargo, North Dakota, United States
Oklahoma City, Oklahoma, United States
Cranberry Township, Pennsylvania, United States
Kingston, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Florence, South Carolina, United States
Chattanooga, Tennessee, United States
Austin, Texas, United States
Bellaire, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Falls Church, Virginia, United States
Lynchburg, Virginia, United States
Morgantown, West Virginia, United States
South Brisbane, Queensland, Australia
East Melbourne, Victoria, Australia
Fitzroy, Victoria, Australia
Glen Waverley, Victoria, Australia
Nedlands, Western Australia, Australia
Essendon, , Australia
Geelong, , Australia
Melbourne, , Australia
Montreal, Quebec, Canada
Glostrup, Hovedstaden, Denmark
Angers, , France
Avranches, , France
Bordeaux, , France
Montauban, , France
Nice, , France
Strasbourg Cedex, , France
Toulouse, , France
Magdeburg, , Germany
Tel Aviv Yafo, Tel Aviv, Israel
Haifa, , Israel
Haifa, , Israel
Naharia, , Israel
Petakh Tikva, , Israel
Remuera, Auckland, New Zealand
Christchurch, Canterbury, New Zealand
Wellington, , New Zealand
Makati City, , Philippines
Makati City, , Philippines
Makati City, , Philippines
San Juan City, , Philippines
Olsztyn, , Poland
Omsk, , Russian Federation
Samara, , Russian Federation
Derby, Derbyshire, United Kingdom
Greater London, Kent, United Kingdom
London, London, City Of, United Kingdom
Carshalton, Surrey, United Kingdom
Cambridge, , United Kingdom
Edinburgh, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Phoenix, Arizona, United States
Petaluma, California, United States
Fort Myers, Florida, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Dusseldorf, Nordrhein Westfalen, Germany
Berlin, , Germany
London, London, City Of, United Kingdom
Olsztyn, , Poland
Nahariya, , Israel
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials